• Eli Lilly to aquire pain biotech CoLucid for $960 million europeanpharmaceuticalreview
    January 20, 2017
    Eli Lilly and Company will acquire CoLucid Pharmaceuticals for $46.50 per share or approximately $960 million. This all-cash transaction will enhance Lilly’s existing portfolio in pain management for migraine, while adding a potential near-term launch to
PharmaSources Customer Service